1d
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
1d
Queerty on MSNA once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous injection into the left thigh, she developed a mildly pruritic eruption on the right thigh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results